

Author: Judd L.L.
Publisher: Elsevier
ISSN: 0924-977X
Source: European Neuropsychopharmacology, Vol.5, Iss.3, 1995-09, pp. : 261-262
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content




Anxiety disorders in the US: `major public health concern'
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 292, 2000-01 ,pp. :






Managing depressive and anxiety disorders with escitalopram
Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 4, 2006-03 ,pp. :